Table 2.
Actual and predicted protection activities against TMV.
| Compd. | EC50 (μg/mL) a | Actual pEC50 (μM) b | Predicted pEC50 (μM) b | Residual |
|---|---|---|---|---|
| M1 | 255.2 ± 3.2 | 3.239 | 3.249 | −0.010 |
| M2 | 156.4 ± 4.1 | 3.487 | 3.494 | −0.007 |
| M3 | 444.4 ± 2.6 | 3.020 | 3.015 | 0.005 |
| M4 | 208.1 ± 4.2 | 3.356 | 3.351 | 0.005 |
| M5 | 355.9 ± 3.5 | 3.114 | 3.066 | 0.048 |
| M6 | 138.1 ± 3.4 | 3.534 | 3.531 | 0.003 |
| * M7 | 406.9 ± 5.2 | 3.012 | 3.069 | −0.057 |
| M8 | 442.1 ± 4.3 | 3.037 | 3.042 | −0.005 |
| M9 | 486.3 ± 6.3 | 2.988 | 2.994 | −0.006 |
| M10 | 204.6 ± 3.6 | 3.371 | 3.373 | −0.002 |
| M11 | 218.1 ± 5.2 | 3.291 | 3.286 | 0.005 |
| * M12 | 314.6 ± 2.6 | 3.148 | 3.194 | −0.046 |
| M13 | 424.0 ± 1.9 | 3.055 | 3.051 | 0.004 |
| M14 | 319.5 ± 3.7 | 3.111 | 3.083 | 0.028 |
| M15 | 274.3 ± 6.2 | 3.212 | 3.257 | −0.045 |
| M16 | 345.1 ± 3.6 | 3.153 | 3.057 | 0.096 |
| M17 | 198.2 ± 5.2 | 3.363 | 3.349 | 0.014 |
| M18 | 246.6 ± 3.2 | 3.299 | 3.268 | 0.031 |
| * M19 | 211.2 ± 4.2 | 3.358 | 3.295 | 0.063 |
| M20 | 488.2 ± 3.5 | 2.945 | 2.942 | 0.003 |
| M21 | 342.5 ± 4.3 | 3.099 | 3.110 | −0.011 |
| Ribavirin | 436.0 ± 4.3 | / | / | / |
a: Average of three replicates; b: pEC50 = −lg (EC50); *: Samples of the testing set.